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a  b  s  t  r  a  c  t
Dual-speciﬁcity  MAP  kinase  (MAPK)  phosphatases  (MKPs  or DUSPs)  are  well-established  negative  reg-
ulators  of  MAPK  signalling  in  mammalian  cells  and tissues.  By  virtue  of their differential  subcellular
localisation  and  ability  to  speciﬁcally  recognise,  dephosphorylate  and  inactivate  different  MAPK  isoforms,
they  are  key  spatiotemporal  regulators  of  pathway  activity.  Furthermore,  as they  are  transcriptionally
regulated  as downstream  targets  of MAPK  signalling  they  can either  act  as  classical  negative  feedback  reg-
ulators  or  mediate  cross  talk  between  distinct  MAPK  pathways.  Because  MAPKs  and particularly  Ras/ERK
signalling  are  implicated  in  cancer  initiation  and  development,  the  observation  that  MKPs  are  abnormally
regulated  in  human  tumours  has been  interpreted  as  evidence  that these  enzymes  can  either suppress
or  promote  carcinogenesis.  However,  deﬁnitive  evidence  of  such  roles  has  been  lacking.  Here  we review
recent work  based  on  the  use of  mouse  models,  biochemical  studies  and  clinical  data  that  demonstrate  key
roles for  MKPs  in modulating  the  oncogenic  potential  of  Ras/ERK  signalling  and  also  indicate  that  these
enzymes  may  play a  role  in the  response  of  tumours  to certain  anticancer  drugs.  Overall,  this  work  rein-
forces  the  importance  of  negative  regulatory  mechanisms  in modulating  the  activity  of oncogenic  MAPK
signalling  and  indicates  that  MKPs  may  provide  novel  targets  for therapeutic  intervention  in  cancer.
©  2016  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license
(http://creativecommons.org/licenses/by/4.0/).
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1. Dual-speciﬁcity MAP  kinase phosphatases:
spatiotemporal regulators of MAP  kinase signalling
A subfamily of 10 catalytically active dual-speciﬁcity protein
phosphatases are dedicated to the task of negatively regulating
the mammalian mitogen-activated protein kinases (MAPKs) by
dephosphorylating both tyrosine and threonine residues of the
∗ Corresponding author.
E-mail address: s.m.keyse@dundee.ac.uk (S.M. Keyse).
signature T-X-Y motif located within the activation loop of the
kinase [1–3]. These MAPK phosphatases (MKPs or DUSPs) can be
broken down into three subgroups based on sequence homology,
subcellular localisation and substrate speciﬁcity. There are four
inducible nuclear MKPs; DUSP1/MKP-1, DUSP2,  DUSP4/MKP-2 and
DUSP5. Three MKPs; DUSP6/MKP-3, DUSP7 and DUSP9/MKP-4 are
both cytoplasmic and ERK selective while a further three MKPs;
DUSP8, DUSP10/MKP-5 and DUSP16/MKP-7 preferentially inacti-
vate the stress-activated c-Jun amino-terminal kinase (JNK) and
p38 MAPKs (Fig. 1A). These enzymes share a highly conserved
structure comprising of a non-catalytic N-terminal domain and a
C-terminal catalytic domain. The latter contains the highly con-
http://dx.doi.org/10.1016/j.semcdb.2016.01.009
1084-9521/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Fig. 1. (A) List of the mammalian dual speciﬁcity MAP  kinase phosphatases broken down into three groups by sequence similarity, subcellular localisation and substrate
speciﬁcity. The ERK-speciﬁc phosphatases DUSP5 and DUSP6/MKP-3, which are the main subject of the experimental work covered in this review are highlighted in red. ND,
not  determined. (B) Schematics showing the domain structures of DUSP5 and DUSP6/MKP-3 highlighting the disposition of the kinase interaction motif (KIM) and localisation
signals  located within the N-terminal non catalytic domain and the catalytic site within the C-terminal domain.
served protein tyrosine phosphatase (PTPase) active site sequence
(I/V)HCXAGXXR(S/T/G). The N-terminal domain contains a con-
served modular sequence known as the kinase interaction motif
(KIM), which mediates differential recognition and binding of
MAPK substrates and also harbours either nuclear localisation (NLS)
or export (NES) signals, which determine subcellular localisation
(Fig. 1B) [4]. Interestingly, in a subset of MKPs the conformation of
the active site in the absence of substrate is not optimal for cataly-
sis. However, when a MAPK substrate is engaged via the KIM, this
causes an allosteric rearrangement of the active site residues within
the C-terminal catalytic domain resulting in catalytic activation,
a process thought to underpin greater substrate selectivity [5,6].
Finally, The observation that the KIM-mediated binding of MKPs to
their cognate substrates by interaction with the conserved MAPK
common docking (CD) domain does not require phosphorylation
and activation of the MAPK itself has led to the idea that MKPs, by
sequestering inactive MAPKs within either the nucleus or the cyto-
plasm, may  regulate the spatial localisation as well as the duration
and magnitude of signalling [7].
Many of the genes that encode MKPs are themselves highly
inducible and in many cases the activity of one or more MAPK
pathways is responsible for transcriptional up regulation of these
enzymes. Thus, individual MKPs can act as classical negative
feedback regulators of pathway activity, but can also mediate
crosstalk between distinct MAPK modules. The fact that MAPK
signalling and in particular the activity of the Ras–extracellular
signal-regulated kinase (Ras/ERK) pathway is often abnormally
activated in human cancers, suggests that MKPs may also be reg-
ulated as a result of the oncogenic activation of MAPK signalling.
This idea is reinforced by several studies demonstrating that neg-
ative feedback control of Ras/ERK signalling by MKPs may play an
important role in determining the biological outcome of signalling
when upstream components of this pathway such as receptor tyro-
sine kinases (RTKs), Ras isoforms or Braf are mutated and activated
[8,9]. This idea is also supported by numerous observations of
either increased or decreased MKP  expression in malignant dis-
ease, suggesting that these enzymes might play some role in cancer
initiation and/or progression [10,11]. However, despite the large
number of reported studies of MKP  dysregulation the majority of
both in vitro and tumour studies rely heavily on the overexpression
of MKPs and/or correlations between MKP  expression levels and
clinical stage/outcome in relatively small patient cohorts. There is
therefore a need for more deﬁned genetic studies of MKP function
in validated mouse models of cancer in which Ras/ERK signalling is
implicated, coupled with more systematic analyses of MKP  expres-
sion in large clinical cohorts before ﬁrm conclusions can be reached
as to the role and signiﬁcance of MKPs in malignant disease.
Here we  review a number of recent studies using a variety of
approaches including pharmacological and genetic manipulation of
MKP  expression or activity, which point towards speciﬁc roles for
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individual MKPs in either the suppression or promotion of carcino-
genesis in human malignancies in which abnormal activation of the
Ras/ERK pathway is an established driver of cancer development.
Furthermore, there is also an increasing body of evidence sug-
gesting that MKPs may  play an important role in determining the
outcome of either conventional or novel anti-cancer drugs that tar-
get components of this pathway. Overall, these studies indicate that
MKPs play complex and context dependent roles in both tumour
initiation and development and in drug responses, but there are
also indications that under certain circumstances the manipula-
tion of MKP  activity or expression might be used to gain therapeutic
advantage in cancer treatment.
2. ERK-speciﬁc MKPs and cancer
2.1. DUSP6/MKP-3: a potential tumour suppressor
DUSP6/MKP-3 was the ﬁrst MKP  with absolute substrate speci-
ﬁcity for ERK, as opposed to either JNK or p38, to be characterised
[12,13]. The enzyme is cytoplasmic and this, coupled with its
high ERK binding afﬁnity, led to the demonstration that it can
act as both a regulator of and cytoplasmic anchor for ERKs [14].
DUSP6/MKP-3 expression is growth factor inducible and this phos-
phatase plays a key role in the regulation of ﬁbroblast growth factor
(FGF) -dependent ERK activation during early embryonic devel-
opment [15,16]. Despite early confusion as to which Ras effector
pathway signals to the DUSP6/MKP-3 promoter, with both phos-
phatidylinositide 3-kinase (PI3K) and ERK signalling implicated in
its regulation, it is now clear that DUSP6/MKP-3 is an ERK target
gene and that it acts as a classical negative feedback regulator of
ERK activity, both in a developmental context and in primary and
cancer cell lines [16–18]. Furthermore, DUSP6/MKP-3 is one of a
small group of genes that is consistently upregulated in response
to elevated ERK signalling in cancer cells harbouring activating
mutations in either Ras or Braf, where it is presumed to restrain
oncogenic ERK signalling [19–21].
Perhaps the most compelling evidence for a role for DUSP6/MKP-
3 as a tumour suppressor has come from studies of pancreatic
cancer in which 90% of tumours contain activating mutations in
Kras. Although there is no evidence of mutation within the DUSP6
gene, mRNA expression levels are consistently lower in pancreatic
cancer cell lines when compared to immortalised normal pancre-
atic ductal cells [22,23]. Analysis of DUSP6/MKP-3 expression in
pancreatic tumours revealed that protein levels were increased in
early pancreatic intraepithelial neoplasia (PanIN), but then reduced
in more advanced invasive or poorly differentiated tumours, a
result conﬁrmed in a more extensive study [22,24]. At the molecu-
lar level the loss of DUSP6/MKP-3 expression in both pancreatic
tumour cell lines and in advanced pancreatic cancer was corre-
lated with the methylation of CpG sequences in intron 1 of the
DUSP6 gene, suggesting that epigenetic silencing was  responsi-
ble for lower levels of DUSP6 transcription [23]. Overall this data
was interpreted as evidence that DUSP6/MKP-3 is associated with
progression from early PanINs to invasive ductal adenocarcinoma
(PDAC). Similar data has also implicated DUSP6/MKP-3 as a tumour
suppressor in mutant Kras-driven lung tumours, where expression
levels showed an inverse relationship with both growth activity
and histological grade. Loss of heterozygosity of the DUSP6 locus
was also found in 17.7% of lung cancer cases and was associated
with reduced expression levels [25].
In vitro studies seemingly support this interpretation; ectopic
expression of DUSP6/MKP-3 in either pancreatic or lung cancer cells
resulted in the suppression of cell growth and apoptosis [22,25],
while expression of DUSP6/MKP-3 in Hras transformed ﬁbroblasts
caused a signiﬁcant delay in tumour formation after injection into
nude mice [26]. However, the latter studies should be treated with
considerable caution as overexpression of DUSP6/MKP-3 using con-
stitutively active heterologous promoters may  result in complete or
near complete ablation of ERK activity. As ERK activation is known
to be required for S-phase entry and cell proliferation [27,28], it is
possible that the ectopic expression of non-physiological levels of
DUSP6/MKP-3 may  result in artefactual suppression of tumour cell
proliferation and growth. Clearly, mouse models of Ras and Braf-
induced cancers coupled with DUSP6 gene knockout and a more
rigorous assessment of DUSP6/MKP-3 levels in larger cohorts of
human tumours will be instrumental in clarifying the possible role
of DUSP6/MKP-3 as a tumour suppressor.
2.2. DUSP6/MKP-3 may be pro-oncogenic in certain tumour types
While the work outlined above suggests a tumour suppres-
sor role for DUSP6/MKP-3, other studies have indicated that this
phosphatase may  be oncogenic. DUSP6/MKP-3 is upregulated in
human glioblastoma cell lines. Overexpression of DUSP6/MKP-3 in
these cells led to the expected reduction in proliferation rate, but
also affected cell morphology with DUSP6/MKP-3-overexpressing
cells exhibiting a more ﬂattened appearance, lower levels of cel-
lular detachment after stimulation with EGF and an increased
propensity to form colonies in soft agar. Surprisingly, mouse
xenograft experiments showed that tumours arising from glioblas-
toma cells expressing DUSP6/MKP-3 grew signiﬁcantly faster than
non-expressing controls perhaps reﬂecting these changes in cell
adhesion and morphology [29]. Overexpression of DUSP6 has also
been identiﬁed in a subset of mouse melanoma cell lines, where
it is associated with enhanced anchorage-independent growth
and invasive capacity [30] and overexpression of DUSP6/MKP-3
in papillary thyroid carcinoma (PTC) cell lines is associated with
increased cell migration and invasion [31]. However, perhaps the
most persuasive data implicating DUSP6/MKP-3 as a pro-oncogenic
phosphatase has come from a recent study of pre-B cell transfor-
mation in acute lymphoblastoid leukemia (ALL) [32].
Müschen and colleagues noted that the acute activation of onco-
genes such as BCR-Abl or NrasG12D in human pre-B cells invariably
led to cell death. However, the small fraction of cells that sur-
vived and became transformed all exhibited increased expression
of negative regulators of ERK signalling including DUSP6/MKP-3,
the transcription factor ERM (Ets related molecule, also known as
Ets Variant Gene 5, ETV5) and sprouty-2 (Spry-2). These ﬁndings
were extended to pre-B ALL cells, which unlike normal pre-B cells,
were also primed to express negative regulators of the ERK path-
way. This up regulation was  dependent on both BCR-Abl and ERK
activity as evidenced by sensitivity to a tyrosine kinase inhibitor
(TKI) (Imatinib) or MEK  inhibitor (PD325901). Interestingly, DUSP6
mRNA levels were a robust and independent predictor of outcome
for adults with Philadelphia chromosome positive (Ph+) (BRC-
Abl-driven) ALL, with higher than median DUSP6 mRNA levels
correlating with shorter overall survival [32]. To explore the speciﬁc
relevance of DUSP6/MKP-3, B cell lineage and myeloid progeni-
tor cells obtained from the bone marrow of DUSP6−/− mice and
wild-type controls were transformed with BCR-Abl1. Interestingly,
while the myeloid progenitors transformed with BCR-Abl1 showed
a higher colony forming ability in the absence of DUSP6/MKP-
3, indicating a tumour suppressor function, the colony formation
of DUSP6−/− B cell lineage leukaemia was  signiﬁcantly reduced,
consistent with a positive role for this phosphatase in malignant
transformation. In a series of further experiments using conditional
expression of NrasG12D in pre-B cells from wild type and DUSP6−/−
mice, only cells from the wild type mice were susceptible to
transformation and shRNA-mediated knockdown of DUSP6 signiﬁ-
cantly reduced the colony forming ability of human pre-B ALL cells.
Furthermore, the growth of pre-B cells transduced with BCR-Abl
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in the presence of Imatinib was strictly dependent on DUSP6 after
washing out the inhibitor, again showing that pre-B ALL cells are
dependent on robust DUSP6/MKP-3-mediated negative feedback
control of ERK signalling for continued growth and survival [32].
Perhaps the most provocative series of experiments pre-
sented in this study involve the use of a pharmacological
inhibitor of DUSP6/MKP-3 activity to validate the hypothesis that
this phosphatase might be a therapeutic target in human ALL.
BCI (2-benzylidene-3-(cyclohexylamino)-1-Indanone hydrochlo-
ride) was ﬁrst identiﬁed in a screen for compounds which were
able to increase FGF signalling output in Zebraﬁsh embryos
and DUSP6/MKP-3 was identiﬁed as the relevant biological tar-
get. Biochemical studies indicated that BCI speciﬁcally inhibits
DUSP6/MKP-3 by preventing the ERK-dependent allosteric changes
that occur within the active site, thus preventing catalytic acti-
vation [33]. In support of this, BCI caused a rapid increase in
ERK activity in patient-derived Ph+ ALL cells. Furthermore, the
increased ERK signalling was associated with increased levels of
intracellular reactive oxygen species (ROS) and p53-mediated cell
death. When ALL cells with hyperactive ERK were chronically
treated with MEK  inhibitor they adapted to normal growth in
its presence. However, washout of the drug caused a subsequent
“rebound” of ERK activity and sensitised cells to treatment with BCI
by a factor of approximately 6. This strongly suggests that there is a
threshold of ERK-signaling that has to be overcome to trigger BCI-
induced apoptosis. Finally, mouse xenograft experiments using Ph+
ALL cells derived from patients after relapse during ongoing ther-
apy with tyrosine kinase inhibitors showed these to be insensitive
to Imatinib, but signiﬁcantly sensitive to treatment with BCI, indi-
cating that this drug may  be of utility in treating TKI-resistant Ph+
ALL [32].
These experiments demonstrate a lineage speciﬁc effect of
DUSP6/MKP-3, with the phosphatase acting as a tumour suppres-
sor in myeloid cells, but as an essential mediator of malignancy
in pre-B cells and suggest that this undue reliance on negative
feedback regulators of ERK activity may  present a vulnerability
and reveal novel drug targets in pre-B cell malignancy. However,
some caution must be exercised in the interpretation of the exper-
iments using BCI. Although active against DUSP6/MKP-3, this drug
is acknowledged to be both non-speciﬁc with respect to MKPs and
is also relatively toxic. As deletion of DUSP6/MKP-3 is tolerated in
the mouse [34], the whole organism and cellular toxicity exhibited
by BCI is highly likely to reﬂect off-target effects. This interpreta-
tion is also supported by the observed inhibition of PI3-kinase-akt
signalling, coupled with a global reduction in levels of cellular phos-
photyrosine observed in the BCI-treated Ph+ ALL cells. BCI contains
an electrophilic ,-unsaturated ketone moiety, which is often
viewed as a liability in drug development due to non-selective mod-
iﬁcation of cellular nucleophiles. This is acknowledged in a recent
publication in which derivatives of BCI have been synthesised in
an attempt to reduce this toxicity while retaining activity towards
DUSP6/MKP-3 [35]. It will be interesting to determine if these
derivatives, several of which show equivalent or higher potency
as inhibitors of DUSP6/MKP3, but are considerably less toxic, can
also selectively kill transformed pre-B ALL cells.
2.3. DUSP5: a nuclear ERK phosphatase and tumour suppressor
DUSP5 is one of four closely related inducible nuclear MKPs.
However, it is unique within this subgroup that unlike DUSP1/MKP-
1, DUSP2 or DUSP4/MKP-2 it is devoid of activity towards the
stress activated MAPKs, acting as an ERK selective phosphatase
[36]. Furthermore, transcriptional induction of DUSP5 in response
to growth factor stimulation is ERK dependent and it can also
bind and sequester inactive ERK in the nucleus when expressed
in mammalian cells [36,37]. Thus, DUSP5 can be regarded as the
nuclear counterpart of DUSP6/MKP-3 in regulating the spatiotem-
poral activity of the Ras/ERK pathway.
As mentioned previously, both DUSP5 and DUSP6/MKP-3 are
amongst a subset of genes, which are often upregulated in tumours
and cancer cell lines in which Ras/MAPK signalling is activated.
Loss of DUSP5 expression has been detected in advanced gastric
and prostate cancers, where its loss correlates with a poor patient
outcome. Furthermore, the re-expression of DUSP5 in gastric can-
cer cell lines reduced both cell proliferation and colony forming
ability in vitro [38,39]. While these limited studies indicate that
DUSP5 might act as a tumour suppressor, they rely on correlation
between expression level and clinical outcome coupled with over
expression of DUSP5 in vitro. However, a recent study using a com-
bination of genetic and biochemical studies has now provided the
ﬁrst evidence of a bona ﬁde tumour suppressor function for DUSP5
[40].
In order to dissect the role of DUSP5 in Ras-induced tumourige-
nesis, mice were generated in which the DUSP5 gene was  deleted
by homologous recombination and found to be both viable and
fertile. Animals were then studied using the well-established
DMBA/TPA-inducible multi-stage skin carcinogenesis protocol in
which DMBA-induced Hras mutations at codon 61 (HrasQ61L) drive
skin papilloma induction. Mice lacking DUSP5 developed twice
as many skin tumours when compared with wild type animals,
while mice lacking one copy of DUSP5 showed an intermedi-
ate phenotype. Loss of DUSP5 did not inﬂuence the mechanism
of carcinogenesis as 90% of the DUSP5−/− papillomas contained
the signature HrasQ61L mutation, nor was  tumour morphology or
size affected by DUSP5 deletion. In searching for a mechanistic
basis for this increased tumourigenesis, the spatiotemporal regula-
tion of ERK signalling was studied using high-content microscopy,
which allowed both the visualisation and quantiﬁcation of levels
of nuclear and cytoplasmic phospho-ERK (p-ERK) and total ERK
Fig. 2. Loss of the inducible ERK-speciﬁc phosphatase encoded by DUSP5 speciﬁ-
cally affects nuclear ERK signalling and gene expression. Loss of DUSP5 synergises
with mutant HrasQ61L leading to higher levels of nuclear p-ERK. This selectively
up-regulates a small number of ERK target genes, including the gene encoding ser-
pinB2. It is the increased expression of the latter protein that leads to the increased
sensitivity to DMBA/TPA induced skin papillomas in DUSP5 knockout mice.
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in TPA-treated mouse embryo ﬁbroblasts (MEFs). These studies
revealed two  major effects of DUSP5 loss in these cells. Firstly, lev-
els of nuclear p-ERK were signiﬁcantly higher at early times after
TPA stimulation in DUSP5−/− cells compared to wild type MEFs,
a result also conﬁrmed using biochemical cell fractionation. Sec-
ondly, levels of total ERK were much lower in the knockout MEFs
at later times after stimulation. Importantly, both phenotypes could
be reversed by the adenoviral expression of wild-type DUSP5,  but
not a KIM mutant (DUSP5R53/54A), expressed under the control of
the early growth response 1 (Egr1) promoter.
Microarray experiments in TPA-treated MEFs revealed that
DUSP5 loss caused the increased expression of a small subset of
TPA-inducible ERK-dependent genes and that serpinB2 (also known
as plasminogen activator inhibitor 2, PAI2) was expressed at the
highest level after DUSP5 deletion. Furthermore, DUSP5 loss syn-
ergises with mutant HrasQ61L in driving ERK-dependent serpinB2
expression in TPA treated MEFs (Fig. 2). Interestingly, serpinB2
had previously been identiﬁed as a promoter of DMBA–TPA car-
cinogenesis when expressed in the skin of transgenic mice under
the control of the bovine keratin 5 promoter [41] and combining
DUSP5 deletion with loss of serpinB2 completely reversed the sen-
sitivity to carcinogenesis caused by DUSP5 loss. Overall this work
demonstrates that DUSP5 has an essential non-redundant function
in regulating both the activity and localisation of nuclear ERK sig-
nalling and that DUSP5 also acts as a tumour suppressor to limit
the oncogenic potential of mutant HrasQ61L in this cancer model
[40]. At present the precise mechanism by which increased ser-
pinB2 expression promotes tumour development is unclear, but it
may  involve intracellular functions, rather than its canonical role
as a secreted inhibitor of extracellular proteases [42].
It will be very interesting to determine if DUSP5 plays a wider
role as a tumour suppressor in more clinically relevant mouse mod-
els of Hras or Braf-driven cancers such as pancreas, lung or intestinal
tumours and to determine the extent to which it is deregulated
in a wider range of human cancers. Interestingly, mice lacking
DUSP5 also display prolonged eosinophil survival and enhanced
eosinophil effector functions following experimental helminth
infection. Microarray experiments in interleukin-33 (IL-33) stimu-
lated wild type and DUSP5−/− eosinophils also revealed changes in
ERK-dependent gene expression caused by DUSP5 loss [43]. Exper-
iments looking at the expression of genes involved in the regulation
of cell death revealed a novel mechanism by which DUSP5 regulates
eosinophil survival through increased ERK-dependent expression
of the anti-apoptotic BL2 family member BCL-XL. This indicates that
the effects of DUSP5 deletion on gene expression may  be lineage
and/or stimulus speciﬁc. It is therefore possible that DUSP5 loss
may  affect oncogenic ERK signalling differently, depending on the
tissue and cellular context.
3. ERK-speciﬁc MKPs and sensitivity to anti-cancer drugs
In addition to their roles in the genesis and development of
cancer it has long been appreciated that MAPK signalling is an
important determinant of cell and tissue responses to many phys-
ical and chemical agents used in cancer therapy. Thus MKPs, as
regulators of MAPK activity, have also been implicated in mod-
ulating cancer cell/tumour sensitivity to both chemotherapeutic
drugs and radiation. Probably the most widely studied of the MKPs
in this regard is DUSP1/MKP-1, an inducible nuclear MKP, which
shows activity towards all three major MAPKs in the rank order
JNK > p38 = ERK [44]. DUSP1/MKP-1 has been implicated in acquired
or intrinsic resistance to a wide range of anti tumour drugs includ-
ing cisplatin, taxanes, anthracyclins and doxorubicin. In most of
these cases, resistance has been linked with the increased expres-
sion of DUSP1/MKP-1 and its substrate preference for JNK, which is
Fig. 3. In NSCLC cells harbouring activating mutations in the epidermal growth fac-
tor receptor (EGFR) and treated with the tyrosine kinase inhibitor (TKI) Geﬁtinib,
Ras/ERK and PI3-kinase-Akt signalling are inhibited. However, while Akt activity
remains low, Ras/ERK pathway activity recovers. This recovery is driven in part by
the  activity of the Src tyrosine kinase, but also by the loss of expression of the ERK-
speciﬁc phosphatase DUSP6/MKP-3. Loss of DUSP6 expression is secondary to the
continued inhibition of Akt activity by Geﬁnitib, resulting in lower levels of the
transcription factor Ets1, which normally transactivates the DUSP6 gene promoter
to  increase expression. This elevated Ras/ERK pathway activity contributes to TKI
resistance by reducing the level of the pro-apoptotic Bcl2 family protein Bim-EL,
thus promoting cell survival in the continued presence of the drug.
a well-established positive regulator of apoptotic cell death [11].
In contrast, the role of ERK-speciﬁc phosphatases has been less
well deﬁned. However, recent publications have indicated that
these enzymes may  play a more complex role in mediating drug
resistance in human lung cancers with their drug-induced down
regulation facilitating the re-activation of Ras/ERK signalling in
treated cells, thus aiding cell survival and promoting resistance to
therapy.
3.1. Modulation of DUSP6/MKP-3 levels modiﬁes the response to
targeted therapies in lung cancer
Non-small cell lung cancer (NSCLC) is the most prevalent form of
this disease accounting for approximately 85% of cases. Of these, a
signiﬁcant fraction (∼15%) contain activating mutations in the epi-
dermal growth factor receptor (EGFR) making the development and
use of EGFR tyrosine kinase inhibitors (TKIs) a focus of drug therapy
in this disease [45,46]. However, despite the efﬁcacy of these drugs
in target inhibition, only a very small fraction of patients (∼5%)
achieve a near complete tumour response and it has been specu-
lated that a portion of these non-responders may  have intrinsic,
rather than acquired, resistance to TKIs [47]. A recent study has
explored these resistance mechanisms by dissecting out the molec-
ular machinery by which the Ras/ERK pathway is activated after
EGFR inhibition in NSCLC cells [48].
Using cancer cell lines that express mutant forms of EGFR, it
was demonstrated that exposure to the TKI geﬁtinib (Iressa) caused
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cell death in approximately 95% of treated cells. However, the sur-
viving cells were both resistant to the drug and capable of both
proliferating and forming colonies in vitro, a result consistent with
a mechanism of innate resistance. Biochemical analysis of these
cells revealed that although TKI treatment effectively blocked EGFR
activation, it only caused a transient blockade of downstream ERK
activation, with a marked rebound in ERK activity in the contin-
ued presence of the drug. This TKI-induced ERK reactivation was
supressed by a MEK  inhibitor and Ras activity was also essential,
as evidenced by its sensitivity to a dominant negative mutant of
Kras (KrasS17N). Surprisingly, the continued activity of the Ras/ERK
pathway was not due to the activation of non-EGFR RTKs or the
Src tyrosine kinase in these cells [48], the latter of which is known
to cause activation of the Ras/MAPK pathway in cells harbouring
mutant EGFR [49], indicating that ERK must be reactivated by an
additional (as yet undeﬁned) mechanism.
A survey of the expression proﬁles of protein phosphatases
in cells exposed to another EGFR TKI erlotinib (Tarceva) revealed
that the drug caused a signiﬁcant reduction in the expression of
DUSP6/MKP-3, a result conﬁrmed at the mRNA and protein level in
EGFR mutant NSCLC cells in the presence of geﬁtinib. Furthermore,
adenoviral expression of DUSP6 in NSCLC cells in the presence of TKI
blocked the reactivation of ERK despite the continued activation of
Ras and MEK. The loss of DUSP6 expression was secondary to loss
of the transcription factor Ets1, which is known to regulate ERK-
dependent DUSP6/MKP-3 transcription in both ﬁbroblasts and lung
cancer cells [17,18]. In an unexpected twist, it was shown that the
loss of Ets1 expression was due to TKI-mediated inhibition of PI3-
kinase signalling, rather than any change in ERK activity and that
DUSP6 expression could be rescued by expression of a constitutively
active form of Akt. Finally, the mechanism by which the elevated
ERK activity engendered by TKI treatment of NSCLC cells enhances
survival was identiﬁed as the increased ERK-dependent phospho-
rylation of the extra long isoform of the pro-apoptotic BH3 only
Bcl-2 family member Bim (Bim EL) (Fig. 3). This promotes its pro-
teosomal degradation and thus blocks cell death. This study shows
an unexpected convergence of ERK and Akt signalling in the reg-
ulation of Ets1 and its target genes including DUSP6/MKP-3 and
demonstrates that loss of DUSP6/MKP-3 plays a key role in rein-
forcing the increased ERK signalling that is coupled to cell survival
in the face of speciﬁc EGFR inhibitors in NSCLC [48].
In addition to EGFR mutations, a signiﬁcant fraction of NSCLC is
caused by expression of a fusion between echinoderm microtubule-
associated protein-like 4 (ELM4) and the RTK anaplastic lymphoma
kinase (ALK) [50]. These ELM4-ALK positive tumours, like those
with mutations in EGFR, either show a lack of response to ALK-
speciﬁc TKIs such as crizotinib (Xalkori) or relapse with drug
resistant disease [51]. In an attempt to identify molecular mech-
anisms, which might limit the effectiveness of ALK inhibitors,
Hrustranovic et al. [52] studied the effect of inhibiting down-
stream signalling pathways in ELM4-ALK lung adenocarcinoma
cells. They found that inhibitors of ERK signalling were equally
as effective as ALK inhibitors in causing decreased cell growth.
In contrast, constitutive activation of Ras/ERK signalling enabled
cells to survive and even proliferate in the presence of crizotinib,
thus revealing a speciﬁc requirement for ERK signalling in these
lung adenocarcinoma cells. How ELM4–ALK actually engages the
Ras/ERK pathway was unclear, particularly as the fusion protein
lacks the transmembrane domain within ALK that would nor-
mally anchor the RTK within the plasma membrane and facilitate
interactions with downstream effectors. In this regard they inves-
tigated a unique hydrophobic echinoderm microtubule-associated
protein-like protein (HELP) domain within ELM4, reasoning that
this might facilitate membrane association of the ELM4–ALK fusion
and facilitate downstream signalling to ERK. In agreement with this
hypothesis, wild type ELM4–ALK protein localised to discrete intra-
cellular compartments and activated Ras/ERK signalling, while a
mutant lacking the HELP domain showed diffuse staining and failed
to activate ERK [52]. These ﬁndings led to the suggestion that ALK
inhibitors combined with a sub maximal dose of a MEK inhibitor
might be more effective than a TKI such as crizotinib alone. This was
veriﬁed using both in vitro and in vivo (mouse xenograft) experi-
ments in which the combined drug regimen was  far more effective
in blocking both ERK activity and tumour growth when compared
with treatment using either drug alone.
On the basis of these ﬁndings they also hypothesised that
acquired resistance to ALK-speciﬁc TKIs was  highly likely to involve
reactivation of the Ras/ERK pathway and this was conﬁrmed in
experiments in which ELM4–ALK positive lung cancer cells were
rendered drug resistant by chronic exposure to crizotinib. In a series
of experiments to determine the likely mechanism of this resis-
tance, exome sequencing revealed an increased copy number for
the gene encoding wild type Kras in one line of crizotinib resistant
cells and in a study of tumour biopsies taken from patients with
acquired resistance to TKI therapy 3 out of 15 patients (20%) had
focal ampliﬁcation of Kras indicating that this is a bona ﬁde resis-
tance mechanism to ALK-speciﬁc TKIs in lung adenocarcinoma.
However, other TKI resistant cell lines had relatively low Ras activ-
ity, but still displayed high basal ERK activation, indicating that
other mechanisms are at play in the rescue of Ras/ERK activity
in these cells [52]. A survey of dual-speciﬁcity MKP  expression in
parental and drug resistant ELM4–ALK lung cancer cells revealed
that while the parental cells had high levels of DUSP6 mRNA expres-
sion the drug resistant cells consistently had lower levels of this
phosphatase. Stable reconstitution of DUSP6/MKP-3 restored both
sensitivity to crizotinib and the ability of this drug to supress
ERK signalling while shRNA-mediated knockdown of DUSP6/MKP-3
promoted crizotinib resistance in parental ELM4–ALK lung ade-
nocarcinoma cells and this was accompanied by rescue of ERK
activation. Finally, in a survey of either drug naïve (n = 15) or drug
resistant (n = 10) ELM4–ALK patient tumours DUSP6/MKP-3 protein
levels as detected and scored by immunohistochemical staining
were signiﬁcantly lower in the drug resistant samples, while in 5
out of 6 (80%) of paired tumour biopsies from patients taken either
before or after drug treatment DUSP6 expression was lower in the
resistant samples. Taken together, these biochemical and clinical
studies strongly implicate the down regulation of DUSP6/MKP-3 as
a driver of ERK-dependent resistance to TKI therapy in ELM4–ALK
positive lung adenocarcinomas [52].
Either mutations in EGFR or expression of the ELM4–ALK fusion
drive tumourigenesis in almost 20% of NSCLC cases worldwide. In
both cases either acquired or intrinsic resistance to EGFR or ALK-
targeted TKIs is driven by reactivation of the Ras/ERK signalling
pathway and a major factor in this reactivation and the genesis of
drug resistance is loss of DUSP6/MKP-3. In the case of EGFR mutant
tumours, DUSP6/MKP-3 loss appears secondary to down regulation
of the transcription factor and ERK signalling target Ets1, while
the mechanism of DUSP6/MKP-3 down regulation in ELM4–ALK
tumour cells was not studied. It will be interesting to see if similar
mechanisms operate in other tumour types and there are indica-
tions that this may  well be the case. For instance, the prolonged use
of MET  (hepatocyte growth factor receptor [HGFR]) RTK inhibitors
in gastric cancer cell lines in vitro results in loss of DUSP6/MKP-3
expression, which correlates with increased levels of p-ERK [53]
while loss of DUSP6/MKP-3 in ovarian cancer has also been linked
with cisplatin resistance [54].
4. Conclusions and remarks
From the experimental evidence reviewed above it is now clear
that dual-speciﬁcity MAP  kinase phosphatases play a key role in
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the regulation and outcome of oncogenic signalling through the
Ras/ERK pathway. From studies of the inducible nuclear phos-
phatase DUSP5,  it is also clear that these effects can reﬂect not only
their activity towards the ERK1/2 MAP  kinases but also their spatial
localisation. Perhaps not surprisingly, individual MKPs can exhibit
either tumour suppressor function or can act as pro-oncogenic reg-
ulators of Ras/ERK signalling and this may  depend on the differing
and tissue-speciﬁc thresholds of ERK activity that are either permis-
sive for or promote cell proliferation or conversely cause cell cycle
arrest/senescence or cell death. Obviously, where tumour suppres-
sor functions for MKPs are manifest, then speciﬁc inhibition is to
be avoided. However, in those malignancies in which MKPs have a
proven role in promoting tumour growth, then such inhibitors may
be of therapeutic use. As a class of enzymes, cysteine-dependent
protein tyrosine phosphatases, of which the MKPs are a subfam-
ily, have been amongst the most difﬁcult targets against which
to develop speciﬁc inhibitors [55]. However, the emergence of
chemical entities, which target the allosteric activation of MKPs,
which occurs on MAPK binding, rather than the active site itself,
offer the promise that more selective and less toxic agents can be
developed and tested. Finally, studies of the regulation and role of
DUSP6/MKP-3 in cellular responses to RTK inhibitors have revealed
that loss of function may  play a key role in resistance to these drugs.
This reinforces the importance of signalling plasticity and pathway
remodelling in the emergence of drug resistance and it is perhaps
no surprise that MKPs, as major regulators of MAPK activity, are
key players in this process.
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